Moderna price target raised to $38 from $34 at BofA
BofA raised the firm's price target on Moderna to $38 from $34 and keeps an Underperform rating on the shares. Limited surprises are expected from the Q2 print given prior revenue guidance and recent pipeline updates, with focus likely on updated 2H catalyst timing, pricing and access developments for approved vaccine programs, and confirmation of revenue growth and operating expense reduction targets, the analyst tells investors in a research note.
BofA raised the firm's price target on Moderna to $38 from $34 and keeps an Underperform rating on the shares.
Limited surprises are expected from the Q2 print given prior revenue guidance and recent pipeline updates, with focus likely on updated 2H catalyst timing, pricing and access developments for approved vaccine programs, and confirmation of revenue growth and operating expense reduction targets, the analyst tells investors in a research note.